



Eric Drapé

Independent Member of the Board of Directors

Lonza Group Ltd

Eric Drapé has been an Independent Member of the Board of Directors of Lonza Group Ltd since 2025.

For more than 35 years, Eric has served in multiple leadership roles in the pharmaceutical industry at Teva Pharmaceuticals, Ipsen Pharma and Novo Nordisk. He has a wealth of international experience, having held positions in Denmark, France, Israel and the US.

Eric is a Member of Lonza's Remuneration Committee, which is responsible for reviewing and recommending compensation policies and plans, agreeing employment terms and evaluating the performance of the Executive Committee and the Chief Executive Officer.

He is also a Member of the Audit and Compliance Committee, which is in charge of overseeing the systems of internal control and financial reporting, and compliance with laws and regulations, including the reporting and assurance process for ESG.

Career

Current Activities and Functions

Public Company Boards

- | | |
|----------------|--|
| 2025 – present | Independent Member of the Board of Directors, Lonza Group Ltd |
| 2025 – present | Independent Member of the Board of Directors, Laboratoires Guerbet |

Further Activities and Functions

- | | |
|----------------|---|
| 2025 – present | Member of the Board of Directors, Eukarÿs |
| 2018 – present | Independent Member of the Board of Directors, LFB |

Former Activities and Functions

- | | |
|-------------|---|
| 2019 – 2024 | EVP, Head of Global Operations, Company Officer and Member of the Executive Committee, Teva |
|-------------|---|
-

2017 – 2022	Member of the Board, Teva-Takeda Business Venture, Japan
2015 – 2019	EVP and Chief Quality Officer, Teva
2014 – 2017	Head of Biologics Operations, Teva
2014 – 2015	Senior VP, Technical Operations Steriles, Respiratory and Biologics, Teva
2007 – 2014	Executive VP, Technical Operations, Ipsen Pharma
2004 – 2007	Independent Member of the Board of Directors, NNE Pharmaplan France
2004 – 2007	Senior VP, Diabetes Finished Products, Novo Nordisk
1994 –2001	Independent Member of the Board of Directors, A3P
1990 –2004	Increasingly senior roles in Quality and as a Site Head in Novo Nordisk
1987 –1990	Analytical Development roles in Air Force R&D and Servier

Education

Doctorate in Pharmacy and a DESS in Analytical Chemistry from Paris XI (FR)
Executive MBA from SIMI (now Copenhagen Business School) (DK)